CD33 and acute myeloid leukemia: Bispecific T cell conjugator (BiTE) targeting CD33 can activate and amplify T cells in autologous clinical samples of patients with AML, and mediate the lysis of primary AML cells and normal myeloid cells in vitro in a dose-dependent manner (75–77).